Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee; Notice of Meeting-Guardant Shield Blood Collection Kit, 30383-30384 [2024-08656]
Download as PDF
Federal Register / Vol. 89, No. 79 / Tuesday, April 23, 2024 / Notices
are a critical first step to understanding
whether further studies or action is
needed to protect public health.
Because often data on these topics are
not collected as part of routine
healthcare delivery or via established
Federal surveys, FDA requires the
development and validation of novel
instruments (i.e., interview and focus
group guides, questionnaires) and
approaches to gathering data on
emerging safety issues the methods used
to create and validate these instruments
may include interviews, focus groups,
small group discussions, pilot and test/
re-test survey launches, and external
validation against benchmark surveys.
In conducting research in these areas,
FDA will need to employ the following
Further, in addition to overseeing the
safety of drug products when used
according to approved drug labeling or
as directed by a healthcare provider, the
Center for Drug Evaluation and Research
(CDER) conducts studies on topics
related to the safe and effective use of
drug products, and emerging safety
issues in areas such as nonmedical use
of approved drug products, use of
unapproved and falsified (i.e.,
counterfeit, fake) drug products, use of
botanical substances (e.g., cannabis
derived products), controlled substance
prescribing decisions, bystander
response to drug overdoses, and
potentially false or misleading
information about drug products.
Reliable data on these and related topics
30383
validation methodology: (1) research to
assess knowledge, perceptions, and
experiences related to topics in the
above-mentioned areas with specific
target populations; (2) techniques to
evaluate sampling and recruitment
methods; and (3) evaluations of the
validity and reliability of survey
questionnaires in target populations.
Annually, FDA projects about 25
social and behavioral studies using the
variety of test methods listed in this
document. FDA is revising this burden
to account for the number of studies we
have received in the last 3 years and to
better reflect the scope of the
information collection.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Interviews and Surveys ...............................................
1 There
I
126,770
I
1
I
Total annual
responses
Average burden
per response
Total
hours
126,770
0.25 (15 minutes) ........................................................
31,693
are no capital costs or operating and maintenance costs associated with this collection of information.
Food and Drug Administration
recommendations to the Agency on
FDA’s regulatory issues. The meeting
will be open to the public.
DATES: The meeting will take place
virtually on May 23, 2024, from 9:30
a.m. to 5:30 p.m. Eastern Time.
ADDRESSES: All meeting participants
will be heard, viewed, captioned, and
recorded for this advisory committee
meeting via an online teleconferencing
and/or video conferencing platform.
Answers to commonly asked questions
about FDA advisory committee
meetings, including information
regarding special accommodations due
to a disability may be accessed at:
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/ucm408555.
htm.
[Docket No. FDA–2024–N–0008]
FOR FURTHER INFORMATION CONTACT:
Based on a review of the information
collection since our last request for
OMB approval, our burden estimate for
this information collection reflects an
overall increase of 17,300 responses
with a corresponding increase of 4,325
hours. We attribute this adjustment to
the need to validate information in
specific areas.
Dated: April 18, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024–08655 Filed 4–22–24; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Molecular and Clinical Genetics Panel
of the Medical Devices Advisory
Committee; Notice of Meeting—
Guardant Shield Blood Collection Kit
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
ddrumheller on DSK120RN23PROD with NOTICES1
Number of
responses
per
respondent
Number of
respondents
Activity
Notice.
The Food and Drug
Administration (FDA or the Agency)
announces a forthcoming public
advisory committee meeting of the
Molecular and Clinical Genetics Panel
of the Medical Devices Advisory
Committee. The general function of the
committee is to provide advice and
SUMMARY:
VerDate Sep<11>2014
17:48 Apr 22, 2024
Jkt 262001
Jarrod Collier, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5214, Silver Spring,
MD 20993–0002, Jarrod.Collier@
fda.hhs.gov, 240–672–5763, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last-minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s website at https://
www.fda.gov/AdvisoryCommittees/
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before the meeting.
SUPPLEMENTARY INFORMATION:
Agenda: The meeting presentations
will be heard, viewed, captioned, and
recorded through an online
teleconferencing platform. On May 23,
2024, the committee will discuss, make
recommendations, and vote on
information regarding the premarket
approval application for the Shield test
by Guardant Health, Inc. The proposed
indication for use statement is as
follows: The Shield test is a qualitative
in vitro diagnostic test intended to
detect colorectal cancer derived
alterations in cell-free DNA from blood
collected in the Guardant Blood
Collection Kit. Shield is intended for
colorectal cancer screening in
individuals at average risk of the
disease, age 45 years or older. Patients
with an ‘‘Abnormal Signal Detected’’
may have colorectal cancer or advanced
adenomas and should be referred for
colonoscopy evaluation. Shield is not a
replacement for diagnostic colonoscopy
or for surveillance colonoscopy in highrisk individuals. The test is performed
at Guardant Health, Inc.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its website prior to the
meeting, the background material will
E:\FR\FM\23APN1.SGM
23APN1
ddrumheller on DSK120RN23PROD with NOTICES1
30384
Federal Register / Vol. 89, No. 79 / Tuesday, April 23, 2024 / Notices
be made publicly available on FDA’s
website at the time of the advisory
committee meeting, and the background
material will be posted on FDA’s
website after the meeting. Background
material and the link to the online
teleconference meeting room will be
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down and select the
appropriate advisory committee meeting
link. The meeting will include slide
presentations with audio components to
allow the presentation of materials in a
manner that most closely resembles an
in-person advisory committee meeting.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before May 10, 2024. Oral
presentations from the public will be
scheduled on May 23, 2024, between
approximately 1:45 p.m. and 2:45 p.m.
Eastern Time. Those individuals
interested in making formal oral
presentations should notify the contact
person (see FOR FURTHER INFORMATION
CONTACT). The notification should
include a brief statement of the general
nature of the evidence or arguments
they wish to present, the names and
addresses of proposed participants, and
an indication of the approximate time
requested to make their presentation on
or before May 7, 2024. Time allotted for
each presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by May 8, 2024.
For press inquiries, please contact the
Office of Media Affairs at fdaoma@
fda.hhs.gov or 301–796–4540.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Artair Mallett
at Artair.Mallett@fda.hhs.gov or 301–
796–9638 at least 7 days in advance of
the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our website at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/ucm111462.
htm for procedures on public conduct
during advisory committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
VerDate Sep<11>2014
17:48 Apr 22, 2024
Jkt 262001
U.S.C. 1001 et seq.). This meeting notice
also serves as notice that, pursuant to 21
CFR 10.19, the requirements in 21 CFR
14.22(b), (f), and (g) relating to the
location of advisory committee meetings
are hereby waived to allow for this
meeting to take place using an online
meeting platform. This waiver is in the
interest of allowing greater transparency
and opportunities for public
participation, in addition to
convenience for advisory committee
members, speakers, and guest speakers.
The conditions for issuance of a waiver
under 21 CFR 10.19 are met.
Dated: April 18, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024–08656 Filed 4–22–24; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Proposed Collection: Public
Comment Request; Information
Collection Request Title: Ryan White
HIV/AIDS Program Client-Level Data
Reporting System, OMB No. 0906–
0039—Revision
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services.
ACTION: Notice.
AGENCY:
In compliance with the
requirement for opportunity for public
comment on proposed data collection
projects of the Paperwork Reduction Act
of 1995, HRSA announces plans to
submit an Information Collection
Request (ICR), described below, to the
Office of Management and Budget
(OMB). Prior to submitting the ICR to
OMB, HRSA seeks comments from the
public regarding the burden estimate,
below, or any other aspect of the ICR.
DATES: Comments on this ICR should be
received no later than June 24, 2024.
ADDRESSES: Submit your comments to
paperwork@hrsa.gov or mail the HRSA
Information Collection Clearance
Officer, Room 14N39, 5600 Fishers
Lane, Rockville, Maryland, 20857.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and draft
instruments, email paperwork@hrsa.gov
or call Joella Roland, the HRSA
Information Collection Clearance
Officer, at (301) 443–3983.
SUMMARY:
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
When
submitting comments or requesting
information, please include the ICR title
for reference.
Information Collection Request Title:
Ryan White HIV/AIDS Program ClientLevel Data Reporting System, OMB No.
0906–0039—Revision.
Abstract: The Ryan White HIV/AIDS
Program (RWHAP), authorized under
Title XXVI of the Public Health Service
Act, is administered by the HIV/AIDS
Bureau within HRSA. HRSA awards
funding to recipients in areas of the
greatest need to respond effectively to
the HIV epidemic, with an emphasis on
providing life-saving and life-extending
medical care, treatment, and support
services for people with HIV in the
United States.
The RWHAP reporting requirements
include the annual submission of clientlevel data in the Ryan White HIV/AIDS
Program Services Report (RSR). The
RSR is designed to collect information
from grant recipients and their
subawarded service providers, funded
under Parts A, B, C, and D of the
RWHAP statute.
HRSA is requesting a revision of the
current RSR with one proposed update:
SUPPLEMENTARY INFORMATION:
Current Questions
• Within your organization/agency,
identify the number of physicians, nurse
practitioners, or physician assistants
who obtained a Drug Addiction
Treatment Act of 2000 waiver to treat
opioid use disorder with medication
assisted treatment (MAT), [e.g.,
buprenorphine, naltrexone] specifically
approved by the U.S. Food and Drug
Administration.
• How many of the above physicians,
nurse practitioners, or physician
assistants prescribed MAT (e.g.,
buprenorphine, naltrexone) for opioid
use disorders in the reporting period?
Proposed Change to Question in 2024
RSR Form
• How many physicians, nurse
practitioners, or physician assistants in
your organization prescribed
medications for opioid use disorder
(MOUD) [e.g., buprenorphine,
naltrexone] for opioid use disorders
during the reporting period?
Need and Proposed Use of the
Information: The RWHAP statute
specifies HRSA’s responsibilities in
administering grant funds, allocating
funding, assessing HIV care outcomes
(e.g., viral suppression), and serving
particular populations. The RSR collects
data on the characteristics of RWHAPfunded recipients, their contracted
service providers, and the patients or
clients served. The RSR system consists
E:\FR\FM\23APN1.SGM
23APN1
Agencies
[Federal Register Volume 89, Number 79 (Tuesday, April 23, 2024)]
[Notices]
[Pages 30383-30384]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-08656]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2024-N-0008]
Molecular and Clinical Genetics Panel of the Medical Devices
Advisory Committee; Notice of Meeting--Guardant Shield Blood Collection
Kit
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or the Agency) announces
a forthcoming public advisory committee meeting of the Molecular and
Clinical Genetics Panel of the Medical Devices Advisory Committee. The
general function of the committee is to provide advice and
recommendations to the Agency on FDA's regulatory issues. The meeting
will be open to the public.
DATES: The meeting will take place virtually on May 23, 2024, from 9:30
a.m. to 5:30 p.m. Eastern Time.
ADDRESSES: All meeting participants will be heard, viewed, captioned,
and recorded for this advisory committee meeting via an online
teleconferencing and/or video conferencing platform. Answers to
commonly asked questions about FDA advisory committee meetings,
including information regarding special accommodations due to a
disability may be accessed at: https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.
FOR FURTHER INFORMATION CONTACT: Jarrod Collier, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5214, Silver Spring, MD 20993-0002,
[email protected], 240-672-5763, or FDA Advisory Committee
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC
area). A notice in the Federal Register about last-minute modifications
that impact a previously announced advisory committee meeting cannot
always be published quickly enough to provide timely notice. Therefore,
you should always check the Agency's website at https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate
advisory committee meeting link, or call the advisory committee
information line to learn about possible modifications before the
meeting.
SUPPLEMENTARY INFORMATION:
Agenda: The meeting presentations will be heard, viewed, captioned,
and recorded through an online teleconferencing platform. On May 23,
2024, the committee will discuss, make recommendations, and vote on
information regarding the premarket approval application for the Shield
test by Guardant Health, Inc. The proposed indication for use statement
is as follows: The Shield test is a qualitative in vitro diagnostic
test intended to detect colorectal cancer derived alterations in cell-
free DNA from blood collected in the Guardant Blood Collection Kit.
Shield is intended for colorectal cancer screening in individuals at
average risk of the disease, age 45 years or older. Patients with an
``Abnormal Signal Detected'' may have colorectal cancer or advanced
adenomas and should be referred for colonoscopy evaluation. Shield is
not a replacement for diagnostic colonoscopy or for surveillance
colonoscopy in high-risk individuals. The test is performed at Guardant
Health, Inc.
FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its website prior to the meeting, the
background material will
[[Page 30384]]
be made publicly available on FDA's website at the time of the advisory
committee meeting, and the background material will be posted on FDA's
website after the meeting. Background material and the link to the
online teleconference meeting room will be available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down and
select the appropriate advisory committee meeting link. The meeting
will include slide presentations with audio components to allow the
presentation of materials in a manner that most closely resembles an
in-person advisory committee meeting.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before May
10, 2024. Oral presentations from the public will be scheduled on May
23, 2024, between approximately 1:45 p.m. and 2:45 p.m. Eastern Time.
Those individuals interested in making formal oral presentations should
notify the contact person (see FOR FURTHER INFORMATION CONTACT). The
notification should include a brief statement of the general nature of
the evidence or arguments they wish to present, the names and addresses
of proposed participants, and an indication of the approximate time
requested to make their presentation on or before May 7, 2024. Time
allotted for each presentation may be limited. If the number of
registrants requesting to speak is greater than can be reasonably
accommodated during the scheduled open public hearing session, FDA may
conduct a lottery to determine the speakers for the scheduled open
public hearing session. The contact person will notify interested
persons regarding their request to speak by May 8, 2024.
For press inquiries, please contact the Office of Media Affairs at
[email protected] or 301-796-4540.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
disabilities. If you require accommodations due to a disability, please
contact Artair Mallett at [email protected] or 301-796-9638 at
least 7 days in advance of the meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our website at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. 1001 et seq.). This meeting notice also serves
as notice that, pursuant to 21 CFR 10.19, the requirements in 21 CFR
14.22(b), (f), and (g) relating to the location of advisory committee
meetings are hereby waived to allow for this meeting to take place
using an online meeting platform. This waiver is in the interest of
allowing greater transparency and opportunities for public
participation, in addition to convenience for advisory committee
members, speakers, and guest speakers. The conditions for issuance of a
waiver under 21 CFR 10.19 are met.
Dated: April 18, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024-08656 Filed 4-22-24; 8:45 am]
BILLING CODE 4164-01-P